Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
暂无分享,去创建一个
B. Gazzard | M. Boffito | D. Back | A. Pozniak | M. Nelson | L. Dickinson | G. Moyle | A. Hill | D. Maitland | C. Fletcher
[1] B. Gazzard,et al. Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients , 2004, Journal of acquired immune deficiency syndromes.
[2] M. Kurowski,et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir , 2004, AIDS.
[3] M. King,et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. , 2004, The Journal of infectious diseases.
[4] B. Gazzard,et al. Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen , 2003, Antiviral therapy.
[5] J. Beijnen,et al. Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir , 2003, Journal of Pharmacology and Experimental Therapeutics.
[6] A. Hill,et al. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects , 2002, HIV medicine.
[7] A. Hsu,et al. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. , 2001, British journal of clinical pharmacology.
[8] B. Sadler,et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers , 2001, AIDS.
[9] J. Beijnen,et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. , 2001, Molecular pharmacology.
[10] P. Reiss,et al. Dose‐Finding Study of a Once‐Daily Indinavir/Ritonavir Regimen , 2000, Journal of acquired immune deficiency syndromes.
[11] M. Saag,et al. Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults , 2000, Antimicrobial Agents and Chemotherapy.
[12] J. Drewe,et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. , 1999, Molecular pharmacology.
[13] C. Beglinger,et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. , 1999, Biochemical pharmacology.
[14] Dale J. Kempf,et al. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.
[15] J. Silverman,et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.